Recombinant Human Arginase I (rhArgI) for Patients With Advanced Hepatocellular Carcinoma (HCC): An Adaptive Design Dose Escalation Trial With Addition of Standard Doxorubicin Treatment.

Trial Profile

Recombinant Human Arginase I (rhArgI) for Patients With Advanced Hepatocellular Carcinoma (HCC): An Adaptive Design Dose Escalation Trial With Addition of Standard Doxorubicin Treatment.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Mar 2012

At a glance

  • Drugs BCT 100 (Primary) ; Doxorubicin
  • Indications Liver cancer
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 13 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Oct 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top